Jakub Otáhal Selected Research

homocysteic acid

1/2021	Treatment With Resveratrol Ameliorates Mitochondrial Dysfunction During the Acute Phase of Status Epilepticus in Immature Rats.
1/2012	Brain superoxide anion formation in immature rats during seizures: protection by selected compounds.
6/2009	Posttreatment with group II metabotropic glutamate receptor agonist 2R,4R-4-aminopyrrolidine-2,4-dicarboxylate is only weakly effective on seizures in immature rats.
3/2008	Anticonvulsant and neuroprotective effect of (S)-3,4-dicarboxyphenylglycine against seizures induced in immature rats by homocysteic acid.
9/2006	Effect of free radical spin trap N-tert-butyl-alpha-phenylnitrone (PBN) on seizures induced in immature rats by homocysteic acid.
4/2005	Seizures induced in immature rats by homocysteic acid and the associated brain damage are prevented by group II metabotropic glutamate receptor agonist (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jakub Otáhal Research Topics

Disease

10	Epilepsy (Aura) 01/2022 - 10/2005
9	Seizures (Absence Seizure) 01/2018 - 04/2005
4	Status Epilepticus (Complex Partial Status Epilepticus) 01/2022 - 01/2005
2	Mitochondrial Diseases (Mitochondrial Disease) 01/2021 - 09/2018
1	Brain Neoplasms (Brain Tumor) 11/2013
1	Partial Epilepsies (Epilepsy, Partial) 01/2011
1	Ischemia 01/2007
1	Stroke (Strokes) 07/2006
1	Sclerosis 10/2005

Drug/Important Bio-Agent (IBA)

6	homocysteic acidIBA 01/2021 - 04/2005
6	Anticonvulsants (Antiepileptic Drugs)IBA 09/2018 - 04/2005
4	Metabotropic Glutamate Receptors (Metabotropic Glutamate Receptor)IBA 10/2014 - 04/2005
4	Neuroprotective AgentsIBA 06/2009 - 04/2005
3	Pilocarpine (Ocusert)FDA LinkGeneric 01/2022 - 09/2018
3	AntioxidantsIBA 01/2021 - 01/2012
3	GlycogenIBA 06/2009 - 04/2005
3	Glucose (Dextrose)FDA LinkGeneric 06/2009 - 04/2005
3	Lactic Acid (Lactate)FDA LinkGeneric 06/2009 - 04/2005
2	ResveratrolIBA 01/2021 - 09/2018
2	fluoro jadeIBA 01/2012 - 09/2006
2	4-aminopyrrolidine-2,4-dicarboxylic acidIBA 06/2009 - 04/2005
2	Endothelin-1 (Endothelin 1)IBA 01/2007 - 07/2006
1	sulforaphaneIBA 01/2022
1	pyridineIBA 01/2021
1	Kainic Acid (Kainate)IBA 01/2021
1	PolyphenolsIBA 01/2021
1	hydroethidineIBA 01/2012
1	Superoxides (Superoxide)IBA 01/2012
1	carbogenIBA 01/2011
1	Pharmaceutical PreparationsIBA 01/2011
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 07/2009
1	Vasoconstrictor AgentsIBA 01/2007
1	phenyl-N-tert-butylnitroneIBA 09/2006
1	Free Radical ScavengersIBA 09/2006
1	Free RadicalsIBA 09/2006
1	Adenosine Triphosphate (ATP)IBA 09/2006
1	EnzymesIBA 10/2005
1	NAD (NADH)IBA 10/2005
1	Electron Transport Complex IV (Cytochrome c Oxidase)IBA 01/2005

Therapy/Procedure

4	Therapeutics 01/2021 - 01/2012
3	Intraventricular Infusions 01/2012 - 04/2005
1	Operative Surgical Procedures 11/2013
1	Drug Therapy (Chemotherapy) 03/2008